RCM
NBIX icon

Requisite Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Requisite Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,873
Closed -$403K – 290
2025
Q3 		$403K Buy
+2,873
New +$389K 0.07% 150

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Requisite Capital Management's NBIX Position: Q4 2025 in Review

Requisite Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 2,873 shares — an estimated $403K sold.

Requisite Capital Management first reported a position in NBIX in Q3 2025 and held it in 1 quarter. The position peaked at $403K in Q3 2025. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Requisite Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Requisite Capital Management sold 2,873 Neurocrine Biosciences shares in Q4 2025, an estimated $403K.
  • Requisite Capital Management first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 1 quarter.
  • Requisite Capital Management's Neurocrine Biosciences position peaked at $403K in Q3 2025.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Requisite Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.